This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.
This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.

Cardiovascular

ADEMPAS logo

ADEMPAS® (riociguat) is licensed as monotherapy or in combination with endothelin receptor antagonists (ERA’s), for the treatment of adult patients with PAH with WHO Functional Class (FC) II to III to improve exercise capacity.1

ADEMPAS (riociguat) is also licensed for the treatment of adult patients with WHO functional class II to III with:

  • inoperable CTEPH
  • persistent or recurrent CTEPH after surgical treatment, to improve exercise capacity.

More information about ADEMPAS (riociguat):

Visit product page

Congress learnings

 

Reference

  1. ADEMPAS Summary of Product Characteristics.

Supporting documentation

ADEMPAS® (riociguat)
Prescribing Information | Summary of Product Characteristics | Patient Information Leaflet

GB-ADE-00274 | Date of Preparation: March 2020